ROPARK (Requip)1 mg – 100 tablet
USD $69.14 Add to cart

ROPARK (Requip)1 mg – 100 tablet

USD $69.14

Each Ropark contains 1 mg Ropinirole Hcl 100 talets per box. It is used to treat Parkinson’s disease and restless legs syndrome.

ATC Classification: N04BC04
Active Ingrediant: Ropinirole Hcl
Generic Name: ROPARK
Manufacturer: Sun Pharma
Strength: 1 mg
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 100 Tab

Examples of Packages sent

Description

Medication Safety Issues

Sound-alike/look-alike issues:

Requip may be confused with Reglan

ROPINIRole may be confused with RisperDAL, risperiDONE, ropivacaine

 

Generic Available (US)

Yes

 

Storage/Stability

Store at 68?F to 77?F (20?C to 25?C). Protect from light.

 

Adverse Reactions

Data inclusive of trials in early Parkinson disease (PD) without levodopa and restless legs syndrome (RLS). Extended-release data from trials in early PD without levodopa. As reported with immediate-release formulation, unless otherwise noted.

>10%:

Cardiovascular: Hypotension (RLS: ?25%; PD: 2%), orthostatic hypotension (RLS: ?25%; PD: 6%; extended release: 14%), hypertension (PD: 5%; extended release: 3% to 15%), syncope (PD: ?12%; RLS: 1% to 2%; sometimes associated with bradycardia)

Central nervous system: Drowsiness (PD: ?40%; extended release: 8% to 15%; RLS: 12%), dizziness (PD: 40%; extended release: 6% to 10%; RLS: 11%), headache (PD, extended release: 5% to 15%)

Gastrointestinal: Nausea (PD: 60%; RLS: 40%; extended release: 10% to 33%), vomiting (PD: 12%; extended release: 10%; RLS: 11%)

Infection: Viral infection (PD: 11%)

Neuromuscular & skeletal: Asthenia (PD: 16%; RLS: 9%), back pain (PD, extended release: 5% to 15%)

1% to 10%:

Cardiovascular: Lower extremity edema (PD: 7%), dependent edema (PD: 6%), chest pain (PD: 4%), flushing (PD: 3%), palpitations (PD: 3%), peripheral ischemia (PD: 3%), atrial fibrillation (PD: 2%), extrasystoles (PD: 2%), peripheral edema (RLS: 2%), tachycardia (PD: 2%)

Central nervous system: Pain (PD: 8%), confusion (PD: 5%), hallucination (PD: 5%), narcolepsy (PD, extended release: 5% to 10%), hypoesthesia (PD: 4%), amnesia (PD: 3%), paresthesia (RLS: 3%), yawning (PD: 3%), lack of concentration (PD: 2%), vertigo (2%)

Dermatologic: Diaphoresis (PD: 6%), hyperhidrosis (RLS: 3%)

Gastrointestinal: Dyspepsia (PD: 10%; RLS: 4%), abdominal pain (PD: 6% to 7%; includes immediate release and extended release), constipation (PD, extended release: 5%), diarrhea (RLS: 5%), xerostomia (PD: 5%; RLS: 3%), anorexia (PD: 4%), flatulence (PD: 3%), upper abdominal pain (RLS: 3%)

Genitourinary: Urinary tract infection (PD: 5%), impotence (PD: 3%)

Hepatic: Increased serum alkaline phosphatase (PD: 3%)

Infection: Influenza (RLS: 3%)

Neuromuscular & skeletal: Increased creatine phosphokinase in blood specimen (PD, extended release: 10%), arthralgia (RLS: 4%), limb pain (RLS: 3%), muscle cramps (RLS: 3%), hyperkinetic muscle activity (PD: 2%)

Ophthalmic: Visual disturbance (PD: 6%), eye disease (PD: 3%), xerophthalmia (PD: 2%)

Respiratory: Nasopharyngitis (RLS: 9%), pharyngitis (PD: 6%), rhinitis (PD: 4%), sinusitis (PD: 4%), bronchitis (PD: 3%), cough (RLS: 3%), dyspnea (PD: 3%), nasal congestion (RLS: 2%)

<1%: Pleural effusion

Postmarketing: Aggressive behavior, agitation, behavioral problems, delirium, delusion, disorientation, heart valve disease, impulse control disorder (Bastiaens 2013; Corvol 2018), interstitial pulmonary disease, mental status changes, paranoid ideation, pleuropulmonary fibrosis, psychiatric disturbance, psychosis

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Brand

Sun Pharma

Reviews

There are no reviews yet.

Be the first to review “ROPARK (Requip)1 mg – 100 tablet”

Your email address will not be published. Required fields are marked *